Ponatinib (IclusigÒ, Incyte Biosciences Distribution BV) is a third generation TKI.

It is more effective than first and second generations TKIs.

It is especially useful for patients with drug resistance caused by the T315I mutation in the BCR‑ABL1 This mutation prevents TKIs from working.

Ponatinib is approved for:

  • Patients with CML and the T315I mutation that prevents any improvement with first- and second-generation TKIs.
  • Ponatinib is not considered as front-line treatment for CML because of its significant cardiovascular side effects. It is not suitable for patients with hypertension, a history of smoking, high cholesterol, and diabetes.